Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.60 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.60 |
| ▸ | HTR6 | P50406 | 7/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17259219 | 0.88 | CACNA1H (0.79) | CACNA1HKCNH2CACNA1GHTR6THRB | |
| SCHEMBL17259265 | 0.86 | CACNA1H (0.76) | CACNA1HKCNH2CACNA1GHTR6POLB | |
| SCHEMBL17259256 | 0.80 | CACNA1H (0.67) | CACNA1HKCNH2CACNA1GHTR6POLB | |
| SCHEMBL17259270 | 0.76 | CACNA1H (0.60) | CACNA1HKCNH2CACNA1GHTR6POLB | |
| SCHEMBL17259260 | 0.75 | KCNH2 (1.00) | CACNA1HKCNH2CACNA1GHTR6 | |
| SCHEMBL17259246 | 0.72 | KCNH2 (0.87) | CACNA1HKCNH2CACNA1GHTR6 | |
| SCHEMBL23401061 | 0.70 | CACNA1H (0.53) | CACNA1HKCNH2CACNA1GHTR6POLB | |
| SCHEMBL17259234 | 0.70 | CACNA1H (0.53) | CACNA1HKCNH2CACNA1GHTR6POLB | |
| SCHEMBL17259274 | 0.69 | KCNH2 (0.85) | CACNA1HKCNH2CACNA1GHTR6 | |
| SCHEMBL17259308 | 0.69 | KCNH2 (0.85) | CACNA1HKCNH2CACNA1GHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493423-B2 | Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-11-15 | — | — | US | claimed |
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-11-19 | — | — | US | claimed |
| US-9493423-B2 | Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CACNA1B, CACNA1F, CACNA1G | CACNA1H 9/4885KCNH2 33/4885CACNA1G 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.